Replimune Company Leadership
| REPL Stock | USD 5.10 0.09 1.80% |
Replimune's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Replimune Group suggests that most insiders are panicking. Replimune employs about 331 people. The company is managed by 12 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 27.58 employees per reported executive.
| Robert Coffin CEO President CEO, Director |
Replimune's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-05-16 | Sushil Patel | Disposed 20194 @ 6.47 | View | ||
| 2023-11-16 | Konstantinos Xynos | Disposed 7313 @ 10.92 | View | ||
| 2023-09-11 | Pamela Esposito | Disposed 5358 @ 20.01 | View | ||
| 2023-08-22 | Pamela Esposito | Disposed 18600 @ 20.01 | View | ||
| 2023-08-11 | Pamela Esposito | Disposed 1400 @ 20 | View | ||
| 2023-07-10 | Pamela Esposito | Disposed 20000 @ 21.58 | View | ||
| 2023-06-13 | Tanya Lewis | Disposed 12860 @ 24.06 | View |
Monitoring Replimune's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Replimune |
Replimune's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Replimune's future performance. Based on our forecasts, it is anticipated that Replimune will maintain a workforce of about 330 employees by July 2024.Replimune Management Team Effectiveness
The company has return on total asset (ROA) of (0.2566) % which means that it has lost $0.2566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4642) %, meaning that it created substantial loss on money invested by shareholders. Replimune's management efficiency ratios could be used to measure how well Replimune manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.46. The value of Return On Capital Employed is expected to slide to -0.56. Net Tangible Assets is expected to rise to about 496.6 M this year, although the value of Total Assets will most likely fall to about 359.6 M.The value of Common Stock Shares Outstanding is expected to slide to about 47.1 M. Net Loss is expected to rise to about (100.9 M) this year
Replimune Workforce Comparison
Replimune Group is currently regarded as top stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 392. Replimune totals roughly 331 in number of employees claiming about 84% of equities under Health Care industry.
Replimune Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Replimune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Replimune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Replimune insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-09-01 | 0.5294 | 9 | 17 | 253,988 | 207,566 |
| 2023-06-01 | 1.4118 | 24 | 17 | 1,344,650 | 184,035 |
| 2022-12-01 | 0.5 | 3 | 6 | 58,750 | 40,500 |
| 2022-06-01 | 3.5714 | 25 | 7 | 842,500 | 44,796 |
| 2021-12-01 | 0.0556 | 1 | 18 | 33,000 | 165,288 |
| 2021-09-01 | 0.2632 | 5 | 19 | 52,000 | 313,981 |
| 2021-06-01 | 4.1667 | 25 | 6 | 1,309,081 | 97,489 |
| 2021-03-01 | 0.1702 | 8 | 47 | 125,000 | 522,096 |
| 2020-12-01 | 0.0686 | 7 | 102 | 182,494 | 941,090 |
| 2020-09-01 | 0.1818 | 2 | 11 | 305,000 | 1,100,428 |
| 2020-06-01 | 14.0 | 14 | 1 | 1,018,899 | 445,339 |
| 2019-12-01 | 0.2941 | 5 | 17 | 1,583,767 | 333,767 |
| 2018-12-01 | 1.0 | 1 | 1 | 87,000 | 87,000 |
| 2018-09-01 | 0.9231 | 36 | 39 | 28,367,259 | 25,723,133 |
Replimune Notable Stakeholders
A Replimune stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Replimune often face trade-offs trying to please all of them. Replimune's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Replimune's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Coffin | President CEO, Director | Profile | |
| Philip FSA | Executive Chairman | Profile | |
| Sushil Patel | Chief Officer | Profile | |
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Tanya MS | Chief Officer | Profile | |
| Pamela Esposito | Chief Business Officer | Profile | |
| Emily Hill | Chief Officer | Profile | |
| Paul Bullock | Chief Head | Profile | |
| Andrew Schwendenman | Chief Treasurer | Profile | |
| MBA MD | Chief Officer | Profile | |
| Jean Franchi | CFO, Officer | Profile |
About Replimune Management Performance
The success or failure of an entity such as Replimune Group often depends on how effective the management is. Replimune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Replimune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Replimune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.58) | (0.55) |
The data published in Replimune's official financial statements usually reflect Replimune's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Replimune Group. For example, before you start analyzing numbers published by Replimune accountants, it's critical to develop an understanding of what Replimune's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Replimune's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Replimune's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Replimune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Replimune Group. Please utilize our Beneish M Score to check the likelihood of Replimune's management manipulating its earnings.
Replimune Workforce Analysis
Traditionally, organizations such as Replimune use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Replimune within its industry.Replimune Manpower Efficiency
Return on Replimune Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 651.9K | |
| Net Loss Per Executive | 18M | |
| Working Capital Per Employee | 1.2M | |
| Working Capital Per Executive | 32.8M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Replimune Stock analysis
When running Replimune's price analysis, check to measure Replimune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Replimune is operating at the current time. Most of Replimune's value examination focuses on studying past and present price action to predict the probability of Replimune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Replimune's price. Additionally, you may evaluate how the addition of Replimune to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Replimune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.24) | Return On Assets (0.26) | Return On Equity (0.46) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.